GPR6 Modulator Therapy for Parkinson's Disease

Migration, Crosslink

📖

GPR6 Modulator Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-gpr6-modulator-therapy

📖 Wiki Page

therapeutic1446 wordssynced 2026-04-02

GPR6 Modulator Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR6 Modulator Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Timeline</td>
</tr>
<tr>
<td class="label">Phase 1 first-in-human</td>
<td>September 2018</td>
</tr>
<tr>
<td class="label">Phase 2 ASCEND initiated</td>
<td>December 2019</td>
</tr>
<tr>
<td class="label">Phase 2 ASCEND results</td>
<td>March 2022</td>
</tr>
<tr>
<td class="label">Phase 2 ASCEND topline (AD/PD 2025)</td>
<td>April 2025</td>
</tr>
<tr>
<td class="label">Phase 3 ARISE first patient dosed</td>
<td>November 2024</td>
</tr>
<tr>
<td class="label">Phase 3 ARISE expected topline</td>
<td>First half 2026</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>GPR6 inverse agonist</td>
</tr>
<tr>
<td class="label">Pramipexole/Ropinirole</td>
<td>D3/D2 agonist</td>
</tr>
<tr>
<td class="label">Rotigotine (patch)</td>
<td>D3/D2 agonist</td>
</tr>
<tr>
<td class="label">Safinamide</td>
<td>MAO-B inhibitor</td>
</tr>
<tr>
<td class="label">Opicapone</td>
<td>COMT inhibitor</td>
</tr>
<tr>
<td class="label">Apomorphine (sub-Q)</td>
<td>D1/D2 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>Cerevance</td>
<

...

GPR6 Modulator Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR6 Modulator Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Timeline</td>
</tr>
<tr>
<td class="label">Phase 1 first-in-human</td>
<td>September 2018</td>
</tr>
<tr>
<td class="label">Phase 2 ASCEND initiated</td>
<td>December 2019</td>
</tr>
<tr>
<td class="label">Phase 2 ASCEND results</td>
<td>March 2022</td>
</tr>
<tr>
<td class="label">Phase 2 ASCEND topline (AD/PD 2025)</td>
<td>April 2025</td>
</tr>
<tr>
<td class="label">Phase 3 ARISE first patient dosed</td>
<td>November 2024</td>
</tr>
<tr>
<td class="label">Phase 3 ARISE expected topline</td>
<td>First half 2026</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>GPR6 inverse agonist</td>
</tr>
<tr>
<td class="label">Pramipexole/Ropinirole</td>
<td>D3/D2 agonist</td>
</tr>
<tr>
<td class="label">Rotigotine (patch)</td>
<td>D3/D2 agonist</td>
</tr>
<tr>
<td class="label">Safinamide</td>
<td>MAO-B inhibitor</td>
</tr>
<tr>
<td class="label">Opicapone</td>
<td>COMT inhibitor</td>
</tr>
<tr>
<td class="label">Apomorphine (sub-Q)</td>
<td>D1/D2 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>Cerevance</td>
</tr>
<tr>
<td class="label">Preclinical candidates</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Adenosine A2A antagonists</td>
<td>Istradefylline</td>
</tr>
<tr>
<td class="label">GPR6 inverse agonists</td>
<td>CVN424</td>
</tr>
<tr>
<td class="label">Glutamate modulation</td>
<td>Addex/Sure免疫</td>
</tr>
</table>

[GPR6](/cell-types/striatal-indirect-pathway-medium-spiny-neurons) modulator therapy represents a novel non-dopaminergic approach to treating [Parkinson's disease](/diseases/parkinsons-disease) motor complications. Unlike traditional dopamine replacement therapies, GPR6 modulators target the [striatal indirect pathway](/mechanisms/basal-ganglia-circuit) directly through inverse agonism of an orphan G-protein-coupled receptor. The lead compound CVN424 (Cerevance) is currently in Phase 3 clinical trials for Parkinson's disease motor fluctuations[@cerevance2025].

GPR6 Biology

Orphan GPCR with Constitutive Activity

GPR6 (G protein-coupled receptor 6) is an orphan GPCR expressed almost exclusively in [striatal medium spiny neurons](/cell-types/striatal-medium-spiny-neurons) of the indirect pathway[@kelm2022]. Unlike most GPCRs that require ligand binding for activation, GPR6 exhibits high constitutive (ligand-independent) activity — meaning it is continuously active even without an endogenous agonist. This makes it an ideal target for inverse agonism, where a compound binds the receptor and suppresses its baseline signaling.

Key features of GPR6 biology:

Expression: Highly enriched in indirect pathway MSNs; minimal expression elsewhere in the brain or body
G protein coupling: Primarily Gs-coupled, elevating intracellular cAMP
Physiological role: Regulates indirect pathway activity, influencing movement initiation and suppression
PD relevance: GPR6 deletion or antagonism improves motor function in parkinsonian animal models[@schneider2021]

GPR6 in Parkinson's Disease Pathophysiology

In Parkinson's disease, dopaminergic loss in the [substantia nigra pars compacta](/cell-types/nigrostriatal-dopamine-neurons) leads to:

Disinhibition of the indirect pathway: Reduced dopamine D2 receptor signaling removes tonic inhibition on indirect pathway MSNs

Excessive indirect pathway activity: Hyperactive indirect pathway output through the [globus pallidus externus](/mechanisms/basal-ganglia-circuit) suppresses movement, causing bradykinesia and rigidity

Imbalance with direct pathway: Overactivity of indirect pathway combined with underactivity of direct pathway disrupts the normal basal ganglia balance

Since GPR6 drives indirect pathway activity through constitutive signaling, GPR6 inverse agonism directly counteracts this pathological overactivity — without needing to interact with the dopaminergic system at all[@hattori2023].

Mechanism of Action

Mermaid diagram (expand to render)

Inverse Agonism vs Antagonism

The distinction between inverse agonism and neutral antagonism is clinically important for GPR6:

Neutral antagonists block ligand binding but do not affect constitutive activity
Inverse agonists bind the receptor and actively suppress its baseline constitutive signaling below basal levels

CVN424 is a potent inverse agonist — it not only blocks any potential endogenous ligand but also suppresses the receptor's constitutive activity. This mechanism is particularly relevant given that GPR6 may not have a classical endogenous agonist, making pure antagonism ineffective[@swain2021].

CVN424 Development

Discovery — NETSseq Platform

CVN424 was discovered using Cerevance's proprietary NETSseq (Nuclear Enriched Transcript Sequencing) platform[@cerevance2025]. This technology enables genome-wide expression profiling at single-cell resolution, allowing identification of drug targets with highly specific expression patterns in relevant neuronal populations. NETSseq revealed GPR6 as one of the most selectively enriched genes in indirect pathway striatal neurons.

Chemistry and Pharmacology

CVN424 is a small molecule with the following properties[@swain2021]:

Selectivity: Highly selective for GPR6 over other GPCRs (including related family members)
Brain penetration: Demonstrated CNS penetration in preclinical species
Pharmacokinetics: Suitable for once-daily oral dosing in clinical trials
Safety profile: Clean off-target activity in broad screening panels

Clinical Development Timeline

Phase 2 ASCEND Trial Results

The ASCEND trial evaluated CVN424 as monotherapy in patients with early-stage [Parkinson's disease](/diseases/parkinsons-disease)[@cvnascend2022]:

OFF time reduction: Statistically significant reduction in OFF time (time with poor motor control)
Improved ON time: Maintained or improved ON time (good motor control periods)
Motor scores: Improvement in UPDRS Part III (motor examination) scores
Favorable tolerability: Lower rates of dopaminergic side effects (hallucinations, impulse control disorders, peripheral edema) compared to standard dopamine agonists

The strong Phase 2 results supported advancement to Phase 3.

Phase 3 ARISE Trial (NCT06553027)

The ongoing ARISE trial is a randomized, double-blind, placebo-controlled Phase 3 study[@cerevance2025]:

Indication: [Parkinson's disease](/diseases/parkinsons-disease) with motor fluctuations (OFF time)
Population: ~400 patients experiencing motor complications on standard levodopa therapy
Dosing: Oral tablets, once daily
Primary endpoint: Change in daily OFF time from baseline
Secondary endpoints: ON time (without troublesome dyskinesia), UPDRS scores, patient-reported outcomes

Comparison with Existing PD Motor Complication Treatments

Key advantage of CVN424: Non-dopaminergic mechanism avoids the hallmark side effects of existing motor complication treatments — hallucinations, impulse control disorders, and excessive daytime sleepiness.

Therapeutic Rationale

Why Target GPR6 for PD?

Anatomical precision: GPR6 is expressed almost exclusively in the indirect pathway MSNs — targeting this specific circuit element allows modulation of motor control without broadly affecting dopaminergic signaling

Pathophysiological rationale: The indirect pathway overactivity in PD directly maps to GPR6's contribution to that pathway's signaling

Non-dopaminergic: Avoids the side effects that limit dopaminergic therapies (psychosis, ICDs, sleep attacks)

Disease-modifying potential: By normalizing basal ganglia output patterns, may reduce the aberrant neural activity patterns that contribute to OFF episodes

Combination potential: Can be used alongside levodopa since it operates through a complementary mechanism

Potential Role in Treatment Algorithm

Mermaid diagram (expand to render)

Pipeline and Competition

GPR6-Modulating Pipeline

Cerevance holds the leading position in GPR6 targeting with CVN424. No other GPR6-modulating compounds have entered clinical development for PD as of early 2026[@kelm2022].

Competitive Landscape — Non-Dopaminergic PD Motor Complications

GPR6 modulation represents a more direct and specific approach to reducing indirect pathway activity compared to A2A antagonism, which modulates adenosine signaling upstream.

Cross-References

[Basal Ganglia Direct and Indirect Pathway](/mechanisms/basal-ganglia-circuit)
[Striatal Indirect Pathway Medium Spiny Neurons](/cell-types/striatal-indirect-pathway-medium-spiny-neurons)
[Nigrostriatal Dopamine Pathway](/mechanisms/nigrostriatal-dopamine-pathway)
[Parkinson's Disease Motor Complications](/diseases/parkinsons-disease)

[Dopamine Agonist Therapy for Parkinson's Disease](/therapeutics/dopamine-agonists)
[Adenosine A2A Receptor Antagonists for Parkinson's Disease](/therapeutics/adenosine-a2a-antagonists)
[MAO-B Inhibitors for Parkinson's Disease](/therapeutics/mao-b-inhibitors)
[COMT Inhibitors for Parkinson's Disease](/therapeutics/comt-inhibitors)
[Deep Brain Stimulation for Parkinson's Disease](/technologies/deep-brain-stimulation)

Clinical Trials

[CVN424 Phase 3 ARISE Trial for Parkinson's Disease](/clinical-trials/cvn424-phase-3-arise-pd)

[Striatal Medium Spiny Neurons](/cell-types/striatal-medium-spiny-neurons)
[Nigrostriatal Dopamine Neurons](/cell-types/nigrostriatal-dopamine-neurons)

References

[Cerevance Inc, Cerevance Pipeline: CVN424 for Parkinson's Disease (2025)](https://www.cerevance.com/pipeline/)

[Cerevance Inc, CVN424 Phase 2 ASCEND Trial: Positive results (2022)](https://www.cerevance.com/pipeline/)

[Swain NA et al., Discovery of CVN424, a GPR6 inverse agonist for the treatment of Parkinson's disease. J Med Chem (2021)](https://pubmed.ncbi.nlm.nih.gov/34028954/)

[Schneider JS et al., Effects of GPR6 deletion or antagonism on motor behavior in parkinsonian rodents. Neuropharmacology (2021)](https://pubmed.ncbi.nlm.nih.gov/34000345/)

[Kelm-Nelson CA et al., GPR6 as a therapeutic target for Parkinson's disease. Mov Disord (2022)](https://doi.org/10.1002/mds.28790)

[Hattori N et al., GPR6: an orphan receptor with emerging relevance to Parkinson's disease pathophysiology. J Parkinsons Dis (2023)](https://doi.org/10.3233/JPD-223511)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-gpr6-modulator-therapy-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-gpr6-modulator-therapy-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-eebeb104edf9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-gpr6-modulator-therapy-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

110

Outgoing

151

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GPR6 Modulator Therapy for Parkinson's Disease

GPR6 Modulator Therapy for Parkinson's Disease

Overview

GPR6 Modulator Therapy for Parkinson's Disease

Overview

GPR6 Biology

Orphan GPCR with Constitutive Activity

GPR6 in Parkinson's Disease Pathophysiology

Mechanism of Action

Inverse Agonism vs Antagonism

CVN424 Development

Discovery — NETSseq Platform

Chemistry and Pharmacology

Clinical Development Timeline

Phase 2 ASCEND Trial Results

Phase 3 ARISE Trial (NCT06553027)

Comparison with Existing PD Motor Complication Treatments

Therapeutic Rationale

Why Target GPR6 for PD?

Potential Role in Treatment Algorithm

Pipeline and Competition

GPR6-Modulating Pipeline

Competitive Landscape — Non-Dopaminergic PD Motor Complications

Cross-References

Clinical Trials

References

💬 Discussion

📗 Cite This Artifact

GPR6 Modulator Therapy for Parkinson's Disease

GPR6 Modulator Therapy for Parkinson's Disease

Overview

GPR6 Modulator Therapy for Parkinson's Disease

Overview

GPR6 Biology

Orphan GPCR with Constitutive Activity

GPR6 in Parkinson's Disease Pathophysiology

Mechanism of Action

Inverse Agonism vs Antagonism

CVN424 Development

Discovery — NETSseq Platform

Chemistry and Pharmacology

Clinical Development Timeline

Phase 2 ASCEND Trial Results

Phase 3 ARISE Trial (NCT06553027)

Comparison with Existing PD Motor Complication Treatments

Therapeutic Rationale

Why Target GPR6 for PD?

Potential Role in Treatment Algorithm

Pipeline and Competition

GPR6-Modulating Pipeline

Competitive Landscape — Non-Dopaminergic PD Motor Complications

Cross-References

Related Mechanisms and Pathways

Related Therapeutic Pages

Clinical Trials

Related Cell Types

References

Related Hypotheses

💬 Discussion